Google AI
The Times Australia
News From Asia

.

Agilis Robotics Achieves Milestone with World’s First Robotic-Assisted En Bloc Resection of Bladder Tumour in Collaboration with CUHK

HONG KONG SAR - Media OutReach Newswire - 29 May 2025 - Hong Kong-based Agilis Robotics has reached a major milestone in surgical innovation with the successful completion of the world's first robotic-assisted en bloc resection of bladder tumour (ERBT) in patients.

This clinical trial, conducted with The Chinese University of Hong Kong (CUHK), highlights the Intilume™ System's potential to improve precision and safety in minimally invasive surgeries.

Pictured with the Intilume™ System (from left) Professor Kwok Ka-wai, Co-Founder of Agilis Robotics and Professor in the Department of Mechanical and Automation Engineering at CUHK, Professor Ng Chi-fai, Tzu Leung Ho Professor of Urology, and Dr Peter Chiu Ka-fung, Associate Professor in the Division of Urology.
Pictured with the Intilume™ System (from left) Professor Kwok Ka-wai, Co-Founder of Agilis Robotics and Professor in the Department of Mechanical and Automation Engineering at CUHK, Professor Ng Chi-fai, Tzu Leung Ho Professor of Urology, and Dr Peter Chiu Ka-fung, Associate Professor in the Division of Urology.

The trial, conducted since December 2022, involved eight patients with bladder tumours. All procedures achieved complete tumour removal, and six patients who completed 30-day post-surgery observations showed satisfactory recovery. Two patients remain under observation, with all participants discharged within 1–2 days.

The Intilume™ System
The Intilume™ System is a robotic surgical platform designed to improve precision and stability in minimally invasive procedures. Featuring two dextrous and miniaturised robotic arms (2.8mm–3.5mm in diameter), it enables accurate en bloc tumour resections in confined spaces. Its intuitive controls can reduce reliance on manual dexterity, shorten the learning curve, and enhance outcomes for complex procedures like ERBT.

Conventional resection loop used to perform bladder tumour resection (left) versus the pair of flexible robotic instruments developed by Agilis Robotics (right).
Conventional resection loop used to perform bladder tumour resection (left) versus the pair of flexible robotic instruments developed by Agilis Robotics (right).

Addressing Bladder Cancer Treatment Challenges
Bladder cancer is among the 10 most common cancers globally, with 75% of cases being non-muscle-invasive. ERBT is more effective than conventional transurethral resection (TURBT) in reducing recurrence but requires high surgical expertise and carries bleeding and bladder perforation risks. The Intilume™ System improves stability and precision, minimizing these risks.

Dr. Peter CHIU Ka-fung, Associate Professor in CUHK's Division of Urology, remarked:
"The robotic system increases the stability of ERBT operations, reducing the risks of bleeding and perforation, and enhancing surgical precision. It helps lower the risk of recurrence due to residual tumour tissue and speed up patient recovery.

Future Applications
The Intilume™ System has potential applications beyond bladder cancer, including gastrointestinal, prostate, uterine, and biliary surgeries. Its compatibility with standard endoscopes and adaptable design makes it a versatile tool across various specialties.

This milestone underscores Agilis Robotics' commitment to advancing precision in minimally invasive surgery.

Hashtag: #AgilisRobotics

The issuer is solely responsible for the content of this announcement.

Times Magazine

Why Is Professional Porsche Servicing Important for Performance and Longevity?

Owning a Porsche is a symbol of precision engineering, luxury, and high performance. To maintain t...

6 ways your smartwatch is lying to you, according to science

You check your smartwatch after a run. Your fitness score has dropped. You’ve burnt hardly any...

Has the adoption of electric vehicles led to new forms of electricity theft

Why the concern exists Electric vehicles (EVs) like the Tesla Model 3 or Nissan Leaf shift “fue...

Adobe Ushers in a New Era of Creativity with New Creative Agent and Generative AI Innovations in Adobe Firefly

Adobe (Nasdaq: ADBE) — the global technology leader that unleashes creativity, productivity and ...

CRO Tech Stack: A Technical Guide to Conversion Rate Optimization Tools

The fascinating thing is that the value of this website lies in the fact that creating a high-cali...

How Decentralised Applications Are Reshaping Enterprise Software in Australia

Australian businesses are experiencing a quiet revolution in how they manage data, execute agreeme...

The Times Features

realestate.com.au attracts the buyer for 9 in 10 listed…

New PropTrack data reveals the impact realestate.com.au has on property sales, with the  platfor...

The Hidden Threat Inside Data Centers: Why Fuel Degrada…

Data centers are designed with one overriding objective: uninterrupted operation. To achieve this...

Holidays: How to Book a Flight — and Protect Your Money…

For decades, booking an overseas holiday was a straightforward transaction: choose your destinat...

Olivia Colman, Kate Box to join an exclusive Live Q…

Fresh out of cinemas, JIMPA - the new film by acclaimed director Sophie Hyde (Good Luck to you, ...

Homemade Food: Cheaper Than Takeaway, Healthier Than Yo…

As the cost of living continues to bite across Australia, households are taking a harder look at...

The Coalition wants NDIS reform to focus on 3 things. H…

The government is expected to announce further changes to the National Disability Insurance Sche...

Power Bills: What Are the Options to Decrease What a Fa…

Australian households are being told, repeatedly, to “use less power.” Turn off lights. Shorten...

The Times Launches Dedicated Property Advertising Platf…

In a significant expansion of its digital media offering, The Times has formally launched TimesA...

Can I get a free flu shot? And will it cover ‘super K’?…

For many of us, flu can mean a nasty few weeks of illness. But for the very young and old, and...